New drug combo targets Hard-to-Treat cancers

NCT ID NCT07123415

Recruiting now Disease control Sponsor: Aptabio Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug, APX-343A, alone or with another cancer drug (pembrolizumab) in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. About 110 adults with advanced cancer will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID CANCER ADVANCED SOLID TUMOR (PHASE 1)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Gangnam Severance Hospital, Yonsei University Health System
RECRUITING

Seoul, South Korea

Contact
Seoul National University Bundang Hospital
RECRUITING

Seongnam, South Korea

Contact
Severance Hospital, Yonsei University Health System
RECRUITING

Seoul, South Korea

Contact